Study Finds Weight-Loss Drug Liraglutide Significantly Reduces BMI in Children Under 12

September 11, 2024
Study Finds Weight-Loss Drug Liraglutide Significantly Reduces BMI in Children Under 12
  • A recent study revealed that children taking liraglutide, a medication aimed at weight loss, experienced a significant reduction in body mass index (BMI) by 5.8%, while those on a placebo saw a 1.6% increase in BMI.

  • Lead researcher Dr. Claudia Fox from the Pediatric Obesity Center at the University of Minnesota emphasized that children have had very few options for managing obesity beyond diet and exercise.

  • Amid rising obesity rates, some doctors advocate for the necessity of medications, highlighting the challenges many children face in achieving lifestyle changes.

  • Experts stress the long-term health implications of childhood obesity, which include increased risks of diabetes, heart disease, and social stigmatization.

  • However, experts caution about the need for careful consideration of the drug's risks, especially given the limited data on its long-term use in young children.

  • The study involved 82 children with a mean age of 10, over half of whom faced obesity-related health issues, and showed that younger children had stronger results than previously studied teenagers.

  • The findings were published in the New England Journal of Medicine and presented at the European Association for the Study of Diabetes meeting in Madrid.

  • Without ongoing treatment, children's BMI increased after the trial, indicating the need for continued intervention to maintain weight loss.

  • Dr. Fox advocates for considering weight-loss medications and surgical options for children, arguing that behavioral changes alone may not suffice for significant weight loss.

  • Currently, no medications are approved for treating obesity in children under 12 years old, although liraglutide, marketed as Saxenda, was approved for adolescents in 2020 and adults in 2014.

  • Based on the promising trial results, Novo Nordisk has submitted an application to the FDA seeking approval for liraglutide's use in children aged 6 to under 12.

  • With nearly 20% of children in the U.S. classified as having a high BMI, the prevalence of obesity among children is a growing concern that necessitates urgent action.

Summary based on 10 sources


Get a daily email with more US News stories

More Stories